Targeted drug combo shows promise for rare chest tumors

NCT ID NCT01025089

First seen Jan 11, 2026 · Last updated May 15, 2026 · Updated 15 times

Summary

This study tested whether adding the targeted drug cetuximab to standard chemotherapy before surgery could improve outcomes for people with advanced thymoma or thymic carcinoma. The trial enrolled 18 adults with stage II to IVA disease. Researchers measured how many tumors completely disappeared after treatment and tracked side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THYMOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • City of Hope Medical Center

    Duarte, California, 91010-3000, United States

  • Md Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Memorial Sloan Kettering Cancer Center @ Suffolk

    Commack, New York, 11725, United States

  • Memorial Sloan Kettering Cancer Center at Phelps Memorial Hospital Center

    Sleepy Hollow, New York, 10591, United States

  • Memorial Sloan Kettering West Harrison

    Harrison, New York, 10604, United States

  • Memorial Sloan Kettering at Basking Ridge

    Basking Ridge, New Jersey, 07920, United States

  • Memorial Sloan Kettering at Mercy Medical Center

    Rockville Centre, New York, United States

Conditions

Explore the condition pages connected to this study.